Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. J of Skin 2020, 4 (6), s108. https://doi.org/10.25251/skin.4.supp.108.